Tokyo - Delayed Quote JPY

Takeda Pharmaceutical Company Limited (4502.T)

4,300.00

+88.00

+(2.09%)

At close: 3:30:00 PM GMT+9

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 23 hours ago

TAK
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 5 days ago

4568.T
+1.54%
TAK
NMPA approves BBM and Takeda China’s haemophilia B therapy

Takeda China handles the therapy’s commercialisation in mainland China, Macau and Hong Kong.

Pharmaceutical Technology 11 days ago

TAK
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

The Wall Street Journal 12 days ago

TAK

TKPHF

DSKYF
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 17 days ago

TAK
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 21 days ago

4568.T
+1.54%
TAK
Takeda Canada says Health Canada expands marketing authorization for HyQvia

Takeda (TAK) Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with intravenous immunoglobulin to prevent relapse of neuromuscular disability and impairment in adults. HyQvia is the only up to once monthly subcutaneous immunoglobulin infusion to treat CIDP in Canada and can be administered by a healthcare professional or self-administered with training, so patien

TipRanks 24 days ago

TAK

TKPHF
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of neuromuscular disability and impairment in adults.1

CNW Group 25 days ago

TAK

TKPHF
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

TAK
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks last month

4568.T
+1.54%
TAK
Takeda’s $770M deal deepens Big Pharma’s omics push

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

Pharma Voice last month

TAK
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera. Polycythemia vera is a type of blood cancer. It causes your bone marrow to make too many red blood cells. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class

Benzinga last month

PTGX

TAK
Takeda and Protagonist report topline outcomes from trial of rusfertide

The randomised Phase III trial met its primary endpoint.

Clinical Trials Arena last month

TAK

PTGX
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

TAK
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist Therapeutics (PTGX) and Takeda (TAK) said Monday that a phase 3 study of investigational

PREMIUM
MT Newswires last month

TAK

PTGX
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-i

Business Wire last month

PTGX

TAK

TKPHF
Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments Healthcare, which includes numerous businesses that […]

Insider Monkey last month

TAK
Takeda broadens its deal with BridGene for up to $770m

The companies will work together to develop small molecules using BridGene’s chemoproteomics platform.

Pharmaceutical Technology last month

TAK
EMA approves Takeda’s Takhzyro pre-filled pen option for HAE

The approval is intended for adults and adolescents aged 12 years and above.

Pharmaceutical Technology last month

TAK
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema (HAE).1

PR Newswire last month

TAK

TKPHF

Performance Overview

Return	4502.T	Nikkei 225 (^N225)
YTD	+5.10%	-14.22%
1-Year	+8.97%	-8.60%
3-Year	+31.24%	+26.25%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Takeda Pharmaceutical Company Limited (4502.T)

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

NMPA approves BBM and Takeda China’s haemophilia B therapy

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

Takeda Canada says Health Canada expands marketing authorization for HyQvia

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Takeda’s $770M deal deepens Big Pharma’s omics push

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda broadens its deal with BridGene for up to $770m

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Performance Overview